Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission

NCT02530125 | Terminated Phase 2 Results DMC

• 4 other identifiers: NU 15H08NCI-2015-01415STU00200695P30CA060553
• Study Type: interventional
• Target: 4
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to evaluate pidilizumab and its effect, bad and/or good, on the immune system in relation to its ability to fight cancer cells. Many cancers can be brought to a phase called complete remission (no cancer is found) but have a chance that they may come back. Researchers are working to improve therapy and to find new drugs that lower the chance of disease coming back. This study uses a drug called pidilizumab. The drug targets our immune system. It can change how our immune system finds cancer cells. The drug may kill any remaining cancer cells that we cannot see with computed tomography (CT) scans. The drug, pidilizumab, is being studied in other cancers.

Conditions

Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma

Outcome Measures

Primary Outcomes (1)

• Response to Pidilizumab

  Response will be defined as the proportion of CD4+CD25+PD-L1+ T lymphocytes and CD4+CD62L+CD127+ T lymphocytes responders. Responders are defined as either a) a 50% increase or b) a half standard deviation increase in lymphocyte subsets. Lymphocyte subsets will be evaluated by flow cytometry on peripheral blood obtained at specified time points through the treatment period.

  Baseline to up to 127 days. Study terminated before this timeframe. As a result insufficient data was collected to be analyzed.

Secondary Outcomes (5)

• The Frequency and Severity of Toxicity - Number of Grade 1, 2, 3, 4, and 5, Adverse Events Experienced During Treatment of Pidilizumab Defined by NCI CTCAE v 4.03.

  Start of treatment, and at days 22, 43, 85, 127 and every 3 months for up to 2 years. Due to early termination of the study, AEs for all patients were collected throughout treatment and up to the point of termination of the study.

• Overall Survival (OS)

  From study enrollment until death, or until last contact, assessed up to 2 years. Study terminated before this timeframe. As a result insufficient data was collected to be analyzed.

• Progression Free Survival (PFS)

  Up to 2 years. Study terminated before this timeframe. As a result insufficient data was collected to be analyzed.

• Relapsed Disease

  Up to 2 years. Study terminated before this timeframe. As a result insufficient data was collected to be analyzed.

• Time to Second Line Chemotherapy (TSLC)

  Up to 2 years

Other Outcomes (3)

• Change in Soluble PD-L1 Levels

  Baseline to up to 127 days. Study terminated before this timeframe. As a result insufficient data was collected to be analyzed.

• Levels of Serum Biomarkers of Immune and Inflammatory Response

  Baseline to up to 127 days. Study terminated before this timeframe. As a result insufficient data was collected to be analyzed.

• PD-1 and PD-L1 Pathway Specific Expression Markers

  Baseline to up to 127 days. Study terminated before this timeframe. As a result insufficient data was collected to be analyzed.

Study Arms (1)

Treatment (pidilizumab)

EXPERIMENTAL

Patients receive pidilizumab IV over approximately 5 hours on day 1. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.

Other: Laboratory Biomarker Analysis; Biological: Pidilizumab

Interventions

Laboratory Biomarker Analysis OTHER

Correlative studies

Treatment (pidilizumab)

Pidilizumab BIOLOGICAL

Given IV

Also known as: CT-011

Treatment (pidilizumab)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed de novo DLBCL by the 4th edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues published in 2008; patients with transform lymphoma are excluded; patients with known primary mediastinal large B-cell lymphoma (PMLBCL) are excluded; patients with known c-v-myc avian myelocytomatosis viral oncogene homolog (c-myc) translocation (by fluorescence in situ hybridization) positive DLBCL are eligible for enrollment; c-myc testing prior to study enrollment is not required; availability of diagnostic biopsy samples in encouraged for the exploratory analysis but not required for enrollment; patients with "double-hit" or "triple-hit" lymphoma are eligible for enrollment
• Previously completed anthracycline-based induction chemotherapy with standard regimens including rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP), dose adjusted (DA)-etoposide, prednisone, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide (EPOCH), and rituximab (R), and R-hyper cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, and cytarabine (CVAD); patients need a minimum of 6 cycles of treatment; initial treatment with pidilizumab must be administered between 30-90 days from last dose of induction chemotherapy
• Complete remission (CR) according to the Revised Response Criteria for Malignant Lymphoma after first-line treatment
• Diagnostic CT scans with contrast of chest, abdomen, and pelvis must have been performed within 8 weeks from the first day of the last cycle of R-chemotherapy; a neck CT will be required if the patient had involvement of the neck region at initial diagnosis
• A negative fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/CT scan performed within 8 weeks from the first day of the last cycle of R-chemotherapy and confirming CR, with negative defined as a score of 1-3 on the Deauville 5-point scale used to quantify radionucleotide density in PET scans as determined locally; PET positive/indeterminate lesions which are confirmed on biopsy to harbor no active lymphoma will be considered negative for determination of CR status
• If positive bone marrow involvement at initial diagnosis the patient must have a negative bone marrow biopsy following R-chemotherapy to confirm the CR
• Stage III/IV disease by Ann Arbor Staging
• Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
• Any National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) score; a calculated score required for enrollment
• Absolute neutrophil count (ANC) \>= 1000
• Platelet count \>= 50,000
• Total bilirubin =\< 2 x upper limit of normal (ULN) or if total bilirubin is \> 2 x ULN, the direct bilirubin must be normal
• Alkaline (Alk.) phosphatase =\< 3 x ULN
• Aspartate aminotransferase (AST) =\< 3 x ULN
• Creatinine =\< 2 x ULN or creatinine clearance (CrCl) \> 30 ml/min

You may not qualify if:

• Active malignancy requiring therapy such as radiation, chemotherapy, or immunotherapy; exceptions to this are as follows: localized nonmelanotic skin cancer and any cancer that in the judgment of the investigator has been treated with curative intent and will not interfere with the study treatment plan and response assessment
• Known central nervous system (CNS) involvement
• Prior stem cell transplantation (autologous or allogeneic)
• Persistent diarrhea or malabsorption \> National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 2, despite medical management
• Subjects with known immunodeficiency, known autoimmune disease, or concurrent use of immunomodulatory agents
• Any cancer directed therapies between completion of induction chemotherapy and treatment on protocol
• Known hypersensitivity to murine or chimeric antibodies or proteins
• Presence of co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens; this includes, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Subjects with known human immunodeficiency virus (HIV) infection
• Subjects with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
• Women must not be pregnant or breast-feeding
• Unwillingness or inability to comply with the protocol

Sponsors & Collaborators

• Northwestern University: lead
• Gateway for Cancer Research: collaborator
• National Cancer Institute (NCI): collaborator

Study Sites (2)

Georgia Regents University Medical Center

Augusta, Georgia, 30912, United States

Location

Northwestern University

Chicago, Illinois, 60611, United States

Location

MeSH Terms

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

pidilizumab

Condition Hierarchy (Ancestors)

Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Limitations and Caveats

Study terminated early due to manufacturer decision to discontinue pidilizumab. As a result insufficient data was collected to be analyzed.

Results Point of Contact

• Title: Winter, Jane MD
• Organization: Northwestern University

Jwinter@nm.org

312 695 4033

Study Officials

• Jane Winter, MD

  Northwestern University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 19, 2015
• First Posted: August 20, 2015
• Study Start: September 1, 2015
• Primary Completion: January 1, 2017
• Study Completion: January 1, 2017
• Last Updated: March 19, 2018
• Results First Posted: March 19, 2018

Record last verified: 2017-04

Locations

US (2)